iBio, Inc.

Nasdaq:IBIO

Pharmaceutical Preparations·NEW YORK, NY

CFO

Duran Felipe

Summary Financials

Revenue

$225,000

FY 2025

Adj. EBITDA

-$16.5M

-7313.3% margin

FY 2025

Net Income

-$24.9M

-11069.8% margin

FY 2025

EPS (Diluted)

-$6.50

FY 2025

Stock Price

$2.60

-1.1%

2026-03-06

52W Range

$0.56 – $5.85

P/E Ratio

-0.4x

Market Cap

$90.0M

Cash

$14.2M

FY 2025

Total Debt

$984,000

FY 2025

Net Cash

$13.2M

FY 2025

Enterprise Value

$76.8M

Debt / EBITDA

0.8x

FY 2025

EV / EBITDA

-4.7x

Employees

—

Revenue

$225,000

FY 2025

Adj. EBITDA

-$16.5M

-7313.3% margin

FY 2025

Net Income

-$24.9M

-11069.8% margin

FY 2025

EPS (Diluted)

-$6.50

FY 2025

Stock Price

$2.60

-1.1%

2026-03-06

52W Range

$0.56 – $5.85

P/E Ratio

-0.4x

Market Cap

$90.0M

Cash

$14.2M

FY 2025

Total Debt

$984,000

FY 2025

Net Cash

$13.2M

FY 2025

Enterprise Value

$76.8M

Debt / EBITDA

0.8x

FY 2025

EV / EBITDA

-4.7x

Employees

—